A peptide triple agonist of GLP-1, neuropeptide Y1, and neuropeptide Y2 receptors promotes glycemic control and weight loss
出版年份 2023 全文链接
标题
A peptide triple agonist of GLP-1, neuropeptide Y1, and neuropeptide Y2 receptors promotes glycemic control and weight loss
作者
关键词
-
出版物
Scientific Reports
Volume 13, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2023-06-12
DOI
10.1038/s41598-023-36178-1
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Similar Gut Hormone Secretions Two Years After One Anastomosis Gastric Bypass and Roux-en-Y Gastric Bypass: a Pilot Study
- (2022) David De Bandt et al. OBESITY SURGERY
- Liraglutide + PYY3-36 Combination Therapy Mimics Effects of Roux-en-Y Bypass on Early NAFLD Whilst Lacking-Behind in Metabolic Improvements
- (2022) Valentin Metzner et al. Journal of Clinical Medicine
- A GLP‐1/glucagon (GCG)/CCK 2 receptors tri‐agonist provides new therapy for obesity and diabetes
- (2022) Songfeng Zhao et al. BRITISH JOURNAL OF PHARMACOLOGY
- Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial
- (2022) Tim Heise et al. Lancet Diabetes & Endocrinology
- Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
- (2022) Tadej Battelino et al. Lancet Diabetes & Endocrinology
- Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
- (2022) Qiming Tan et al. Frontiers in Endocrinology
- Hypothalamic NPY-Y1R Interacts with Gonadal Hormones in Protecting Female Mice against Obesity and Neuroinflammation
- (2022) Alessandra Oberto et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Tirzepatide Once Weekly for the Treatment of Obesity
- (2022) Ania M. Jastreboff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves’ Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves’ Orbitopathy (EUGOGO)]
- (2022) Mariusz Nowak et al. Endokrynologia Polska
- The design of a GLP‐1/PYY dual acting agonist
- (2021) Soren Ostergaard et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Design and Evaluation of Peptide Dual-Agonists of GLP-1 and NPY2 Receptors for Glucoregulation and Weight Loss with Mitigated Nausea and Emesis
- (2021) Brandon T. Milliken et al. JOURNAL OF MEDICINAL CHEMISTRY
- Toward a Medical Gastric Bypass: Chronic Feeding Studies With Liraglutide + PYY3-36 Combination Therapy in Diet-Induced Obese Rats
- (2021) Ulrich Dischinger et al. Frontiers in Endocrinology
- Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
- (2021) Maria Mirabelli et al. Journal of Clinical Medicine
- FGF21 Normalizes Plasma Glucose in Mouse Models of Type 1 Diabetes and Insulin Receptor Dysfunction
- (2021) John L Diener et al. ENDOCRINOLOGY
- Peripheral-specific Y1 receptor antagonism increases thermogenesis and protects against diet-induced obesity
- (2021) Chenxu Yan et al. Nature Communications
- Glucagon‐like peptide‐1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?
- (2021) Tito Borner et al. BRITISH JOURNAL OF PHARMACOLOGY
- Conditional Inactivation of Limbic Neuropeptide Y-1 Receptors Increases Vulnerability to Diet-Induced Obesity in Male Mice
- (2021) Silvia Paterlini et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
- (2021) Julio Rosenstock et al. LANCET
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression of glucagon-like peptide 1 receptor in neuropeptide Y neurons of the arcuate nucleus in mice
- (2021) Yvette Ruska et al. Brain Structure & Function
- A novel approach to treating opioid use disorders: Dual agonists of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors
- (2021) Riley Merkel et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- Roux-en-Y Gastric Bypass and Caloric Restriction but Not Gut Hormone-Based Treatments Profoundly Impact the Hypothalamic Transcriptome in Obese Rats
- (2021) Ulrich Dischinger et al. Nutrients
- Neuropeptide Y1 receptor antagonism protects β-cells and improves glycemic control in type 2 diabetes
- (2021) Chieh-Hsin Yang et al. Molecular Metabolism
- Peptide-YY3-36/glucagon-like peptide-1 combination treatment of obese diabetic mice improves insulin sensitivity associated with recovered pancreatic β-cell function and synergistic activation of discrete hypothalamic and brainstem neuronal circuitries
- (2021) Brandon B. Boland et al. Molecular Metabolism
- Insulin-Responsive Transcription Factors
- (2021) Gerald Thiel et al. Biomolecules
- GABA neurons in the nucleus tractus solitarius express GLP-1 receptors and mediate anorectic effects of liraglutide in rats
- (2020) Samantha M. Fortin et al. Science Translational Medicine
- Insulin-independent stimulation of skeletal muscle glucose uptake by low-dose abscisic acid via AMPK activation
- (2020) Mirko Magnone et al. Scientific Reports
- Unusually persistent Gαi-signaling of the neuropeptide Y2 receptor depletes cellular Gi/o pools and leads to a Gi-refractory state
- (2020) Isabelle Ziffert et al. Cell Communication and Signaling
- Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
- (2020) Francis S. Willard et al. JCI Insight
- The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
- (2020) Thinzar Min et al. Diabetes Therapy
- Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion
- (2019) Elisa Vergari et al. Nature Communications
- PYY plays a key role in the resolution of diabetes following bariatric surgery in humans
- (2019) Claudia Guida et al. EBioMedicine
- The PYY/Y2R-Deficient Mouse Responds Normally to High-Fat Diet and Gastric Bypass Surgery
- (2019) Brandon Boland et al. Nutrients
- GLP-1 and PYY3-36 reduce high-fat food preference additively after Roux-en-Y gastric bypass in diet-induced obese rats
- (2019) Ulrich Dischinger et al. Surgery for Obesity and Related Diseases
- Combined loss of GLP-1R and Y2R does not alter progression of high-fat diet-induced obesity or response to RYGB surgery in mice
- (2019) Brandon B. Boland et al. Molecular Metabolism
- Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes
- (2019) Maria Mirabelli et al. International Journal of Environmental Research and Public Health
- A vitamin B12 conjugate of exendin-4 improves glucose tolerance without associated nausea or hypophagia in rodents
- (2018) Elizabeth G. Mietlicki-Baase et al. DIABETES OBESITY & METABOLISM
- MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
- (2018) Philip Ambery et al. LANCET
- Targeting GLP-1 receptor trafficking to improve agonist efficacy
- (2018) Ben Jones et al. Nature Communications
- Chimeric peptide EP45 as a dual agonist at GLP-1 and NPY2R receptors
- (2018) Oleg G. Chepurny et al. Scientific Reports
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- (2018) Juan Pablo Frias et al. LANCET
- PYY(3-36) and exendin-4 reduce food intake and activate neuronal circuits in a synergistic manner in mice
- (2018) Marina Kjaergaard et al. NEUROPEPTIDES
- The Role of PYY in Pancreatic Islet Physiology and Surgical Control of Diabetes
- (2017) Claudia Guida et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Pancreatic PYY Is Critical in the Control of Insulin Secretion and Glucose Homeostasis in Female Mice
- (2015) Yan-Chuan Shi et al. ENDOCRINOLOGY
- GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents
- (2014) Jianping Ye et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Control of Insulin Secretion by Cytochromecand Calcium Signaling in Islets with Impaired Metabolism
- (2014) Austin M. Rountree et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
- (2014) Brian Finan et al. NATURE MEDICINE
- Peripheral activation of the Y2-receptor promotes secretion of GLP-1 and improves glucose tolerance
- (2013) Keval Chandarana et al. Molecular Metabolism
- Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents
- (2012) Jonathan W. Day et al. BIOPOLYMERS
- Selective Ablation of Peptide YY Cells in Adult Mice Reveals Their Role in Beta Cell Survival
- (2012) Amir H. Sam et al. GASTROENTEROLOGY
- A Pharmacological Primer of Biased Agonism
- (2012) Bradley T. Andresen Endocrine Metabolic & Immune Disorders-Drug Targets
- A Role for Metalloendopeptidases in the Breakdown of the Gut Hormone, PYY3–36
- (2011) Melisande L. Addison et al. ENDOCRINOLOGY
- Changes in Dynamic Insulin and Gastrointestinal Hormone Secretion in Obese Children
- (2011) Christian L. Roth et al. JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM
- Neuropeptide Y receptors: ligand binding and trafficking suggest novel approaches in drug development
- (2011) Cornelia Walther et al. JOURNAL OF PEPTIDE SCIENCE
- Effects of Exendin-4 Alone and With Peptide YY3–36 on Food Intake and Body Weight in Diet-Induced Obese Rats
- (2010) Roger D. Reidelberger et al. Obesity
- Control of secretory granule access to the plasma membrane by PI3 kinase-γ
- (2010) Patrick E MacDonald Islets
- A highly energetic process couples calcium influx through L-type calcium channels to insulin secretion in pancreatic β-cells
- (2009) Seung-Ryoung Jung et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus
- (2009) K. Aaboe et al. DIABETES OBESITY & METABOLISM
- Insulin as a physiological modulator of glucagon secretion
- (2008) Pritpal Bansal et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation